Novo Nordisk’s Launches New Insulin Affordability Offerings in the U.S.

Published on
By : dLife Editors

Novo Nordisk launched a handful of new insulin affordability offerings for people living in the U.S.

The new offerings include:

  • My$99Insulin: Patients can purchase up to three vials or two packs of FlexPen®/FlexTouch®/Penfill® pens of any combination of insulins from Novo Nordisk Inc. for $99
  • Follow-on brand insulins: Authorized generics of NovoLog® and NovoLog Mix® made by new Novo Nordisk A/S US company, Novo Nordisk Pharma, Inc., available at pharmacies within 1-3 business days at 50 percent off the list price.
  • Immediate Supply: A new, immediate, one-time insulin supply option available for people facing an acute need when more time is needed to identify a long-term sustainable solution.

The offerings come in light of recent scrutiny of the pharma industry over insulin affordability issues.

Novo Nordisk’s new options, along with information on the existing patient assistance program, copay cards, and where to find $25/vial human insulin, are now available online.

“With these programs, in conjunction with Novo Nordisk Inc.’s investment in rebates to ensure our medicines are on formularies, we are continuing to take action to help people with diabetes afford their insulin as we work toward much needed longer-term change,” commented Doug Langa, executive vice president, North America Operations and president of Novo Nordisk Inc. in a press release.

To learn more about expanded affordability options and to view full eligibility requirements, visit or call 1.844.NOVO4ME (1.844.668.6463).


  1. Novo Nordisk. (2019, Jan. 2). Novo Nordisk’s new insulin affordability offerings are now available in the US. PR Newswire. Retrieved Jan. 6, 2019 from